Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy.
c-jun has been found to be upregulated in a variety of cancers. Recently, this oncogene has also been implicated in liposarcoma (LS) progression. c-jun knockdown mediated by a deoxyribozyme induced apoptosis in LS cells via evoking caspase-10, but not the Fas/FasL pathway. A novel orthotopic model for LS was established in the hindlimb of mice using human cells to extend the evaluation of effects of c-jun knockdown in vivo. Tumor take in vivo was 100%, with growths resembling high grade aggressive LS. The c-jun deoxyribozyme inhibited the growth of LS in this model. Clinically, downregulation of c-jun may proffer an improved treatment outcome for liposarcoma. The new model for LS described here will enable better testing of agents with therapeutic potential against LS.
Dass
Crispin R
CR
Department of Orthopaedics and University of Melbourne Department of Surgery, St. Vincent's Hospital, Fitzroy, Victoria, Australia. cris.dass@yahoo.com
Galloway
Stuart J
SJ
Clark
Jonathan C M
JC
Khachigian
Levon M
LM
Choong
Peter F M
PF
D000328:Adult; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D053455:Caspase 10 / Q000378:metabolism; D045744:Cell Line, Tumor; D021881:DNA, Catalytic / Q000378:metabolism / Q000494:pharmacology; D004195:Disease Models, Animal; D006801:Humans; D007150:Immunohistochemistry; D008080:Liposarcoma / Q000473:pathology*; D008297:Male; D051379:Mice; D016755:Proto-Oncogene Proteins c-jun / Q000235:genetics / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays
D021881:DNA, Catalytic; D016755:Proto-Oncogene Proteins c-jun; D053455:Caspase 10